Home Interviews Cereno’s CEO on being granted “Compassionate Use”

Cereno’s CEO on being granted “Compassionate Use”

Sten R Sörensen, CEO CerenoScientific

Cereno’s CEO on being granted “Compassionate Use”

6 February, 2024

Cereno Scientific has been granted Expanded Access, also known as “compassionate use,” by the FDA for drug candidate CS1 in rare disease pulmonary arterial hypertension. This will ensure that patients who have completed the ongoing phase II clinical study in PAH will have continued access to the drug. Cereno’s CEO Sten R. Sörensen dropped by the BioStock Studio to talk about the importance of this decision.

Watch the interview with Cereno‘s CEO Sten R. Sörensen below.

YouTube video

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev